

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

INSIDE INFORMATION

PROPOSED DUAL LISTING

AND

PROFIT WARNING

FOR THE SIX MONTHS ENDED 30 JUNE 2025

This announcement is made by IVD Medical Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 and Rule 13.10 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

PROPOSED DUAL LISTING

The board of directors of the Company (the “**Board**”) is pleased to announce that it has resolved to proceed with a proposed dual primary listing (the “**Proposed Dual Listing**”) by way of a proposed initial public offering of its American depositary shares (“**ADS**”), representing new ordinary shares of the Company (the “**Shares**”) to be issued, on the Nasdaq Stock Market in the United States (the “**Offering**”).

The Board believes that the Proposed Dual Listing, if proceeded, will create a public market for the ADSs, provide the potential for the Company to broaden its shareholders’ base and its fundraising channels in the future, generate value for shareholders of the Company (the “**Shareholders**”) and enhance the Company’s corporate image in the international capital markets and the liquidity of the Company’s securities in the long run.

The Company’s pursuit of the Proposed Dual Listing is at an early stage. The Proposed Dual Listing will be subject to, among other things, (i) the approvals by the relevant regulatory authorities and stock exchanges in Hong Kong and the United States; (ii) the satisfaction of all conditions necessary for the completion of the Proposed Dual Listing; and (iii) market conditions at the time of the Proposed Dual Listing.

The Company will make further announcement(s) relating to the abovementioned matters as and when appropriate in compliance with the requirements under the Listing Rules to keep the Shareholders and potential investors of the Company informed.

PROFIT WARNING

The Board wishes to inform the Shareholders and potential investors that, based on the information currently available to the Board and preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2025 (the **"Reporting Period"**), it is expected that the Group will record a profit attributable to owners of the parent of not less than RMB33 million for the Reporting Period as compared to the profit attributable to owners of the parent of approximately RMB125 million for the six months ended 30 June 2024. Such decrease was primarily attributable to (i) higher administrative expenses incurred due to labor costs for the Reporting Period; and (ii) an increase in selling and distribution expenses resulting from the technical service fees paid to a prospective partner, an in vitro diagnostics company with chemiluminescence technology and products as its core, for the Reporting Period.

As at the date of this announcement, the Group is still in the process of preparing its unaudited consolidated interim results for the Reporting Period. The information contained in this announcement is only based on the preliminary assessment with reference to the unaudited consolidated management accounts of the Group and information currently available to the Board, which have yet to be finalised and are subject to changes. Shareholders and potential investors should refer to the unaudited consolidated interim results for the Reporting Period, which will be published by the Company pursuant to the requirements of the Listing Rules in due course.

There can be no assurance as to whether or when the Proposed Dual Listing or the Offering may be completed, or as to whether the Company will be able to list the ADSs on the Nasdaq Stock Market. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 14 July 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.